register

News & Trends - Pharmaceuticals

Australia’s first COVID-19 treatment approved

Health Industry Hub | July 13, 2020 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead’s remdesivir (Veklury) as the first treatment option for COVID-19. It has received provisional approval for use in adults and adolescent patients with severe COVID-19 symptoms who have been hospitalised.

Remdesivir is the most promising treatment option so far to reduce hospitalisation time for those suffering from severe coronavirus infections. Remdesivir will not be available to Australians unless they are severely unwell, requiring oxygen or high level support to breathe, and in hospital care.

While this is a major milestone in Australia’s struggle against the pandemic, it is important to emphasise that the product has not been shown to prevent coronavirus infection or relieve milder cases of infection.

On 10 July 2020, Gilead Sciences announced additional data on remdesivir. The data includes a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19. In this analysis, remdesivir was associated with an improvement in clinical recovery and 62% reduction in the risk of mortality compared with standard of care – an important finding that requires confirmation in prospective clinical trials.

Gilead’s analyses of the company’s compassionate use program demonstrated that 83% of paediatric patients (n=77) and 92% of pregnant and postpartum women (n=86) with a broad spectrum of disease severity recovered by Day 28. No new safety signals were identified with remdesivir across these populations. To further the understanding of these results in individual patient cases, Gilead recently announced the initiation of a global, open-label Phase 2/3 trial to evaluate the safety, tolerability and pharmacokinetics of remdesivir in paediatric patients from birth to less than 18 years of age. Gilead is also collaborating on a study for pregnant women.

Selfcare In Healthcare Coalition on Mental Health Support in Pharma, Biotech and MedTech

Australia is the one of the first regulators to authorise the use of remdesivir for the treatment of COVID-19, following on from recent approvals in the U.S., European Union, Japan, and Singapore.

Provisional approval, which is limited to a maximum of six years, was made on the basis of preliminary clinical data, as there is the potential for substantial benefit to Australian patients. The sponsor, Gilead Sciences may apply for full registration when additional clinical data required by the TGA to confirm the safety and efficacy of the medicine are available.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.